Affiliation:
1. Center for the Study of Emerging and Re-Emerging Pathogens
2. Division of Infectious Diseases, Department of Internal Medicine
3. Department of Microbiology and Molecular Genetics, The University of Texas Medical School, Houston, Texas 77030
Abstract
ABSTRACT
Using six
Enterococcus faecalis
and five
Enterococcus faecium
strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Ery
s
) and -intermediate (Ery
i
) enterococci (ABT 50% protective doses [PD
50
s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Ery
r
) strains for which ABT MICs were low, ABT showed much greater activity (PD
50
, 6.3 to 32.5 mg/kg) than ERY (PD
50
, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献